Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.
Saved in:
| Title: | Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I. |
|---|---|
| Authors: | Kummar S; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Heath & Science University School of Medicine, Portland, OR., Song Z; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Reiss KA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Ford JM; Division of Oncology, Stanford University School of Medicine, Stanford, CA., Chen L; Frederick National Laboratory for Cancer Research, Frederick, MD., Rolig AS; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Heath & Science University School of Medicine, Portland, OR., Zwiebel JA; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Gore SD; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Gray RJ; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Wang V; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Patton D; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD., Gross J; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD., Brunnquell D; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD., Jackson LF; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD., Hamilton SR; City of Hope National Medical Center and Comprehensive Cancer Center, Duarte, CA., Takebe N; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Brufsky A; University of Pittsburgh, Pittsburgh, PA., Tricoli JV; Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., O'Dwyer PJ; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Chen AP; Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Flaherty KT; Massachusetts General Hospital, Boston, MA. |
| Source: | JCO precision oncology [JCO Precis Oncol] 2026 Jun; Vol. 10 (6), pp. e2500769. Date of Electronic Publication: 2026 Jun 17. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42308463 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Kummar+S%22">Kummar S</searchLink>; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Heath & Science University School of Medicine, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Song+Z%22">Song Z</searchLink>; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Reiss+KA%22">Reiss KA</searchLink>; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.<br /><searchLink fieldCode="AU" term="%22Ford+JM%22">Ford JM</searchLink>; Division of Oncology, Stanford University School of Medicine, Stanford, CA.<br /><searchLink fieldCode="AU" term="%22Chen+L%22">Chen L</searchLink>; Frederick National Laboratory for Cancer Research, Frederick, MD.<br /><searchLink fieldCode="AU" term="%22Rolig+AS%22">Rolig AS</searchLink>; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Heath & Science University School of Medicine, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Zwiebel+JA%22">Zwiebel JA</searchLink>; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Gore+SD%22">Gore SD</searchLink>; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Gray+RJ%22">Gray RJ</searchLink>; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Wang+V%22">Wang V</searchLink>; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22McShane+LM%22">McShane LM</searchLink>; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Rubinstein+LV%22">Rubinstein LV</searchLink>; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Patton+D%22">Patton D</searchLink>; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Gross+J%22">Gross J</searchLink>; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Brunnquell+D%22">Brunnquell D</searchLink>; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Jackson+LF%22">Jackson LF</searchLink>; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Williams+PM%22">Williams PM</searchLink>; Frederick National Laboratory for Cancer Research, Frederick, MD.<br /><searchLink fieldCode="AU" term="%22Hamilton+SR%22">Hamilton SR</searchLink>; City of Hope National Medical Center and Comprehensive Cancer Center, Duarte, CA.<br /><searchLink fieldCode="AU" term="%22Takebe+N%22">Takebe N</searchLink>; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Brufsky+A%22">Brufsky A</searchLink>; University of Pittsburgh, Pittsburgh, PA.<br /><searchLink fieldCode="AU" term="%22Tricoli+JV%22">Tricoli JV</searchLink>; Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Conley+BA%22">Conley BA</searchLink>; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Arteaga+CL%22">Arteaga CL</searchLink>; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX.<br /><searchLink fieldCode="AU" term="%22Harris+LN%22">Harris LN</searchLink>; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22O'Dwyer+PJ%22">O'Dwyer PJ</searchLink>; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.<br /><searchLink fieldCode="AU" term="%22Chen+AP%22">Chen AP</searchLink>; Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Flaherty+KT%22">Flaherty KT</searchLink>; Massachusetts General Hospital, Boston, MA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101705370%22">JCO precision oncology</searchLink> [JCO Precis Oncol] 2026 Jun; Vol. 10 (6), pp. e2500769. <i>Date of Electronic Publication: </i>2026 Jun 17. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase II – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101705370 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-4284 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224734284%22">24734284 </searchLink><i>NLM ISO Abbreviation: </i>JCO Precis Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42308463 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1200/PO-25-00769 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e2500769 Titles: – TitleFull: Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Kummar S – PersonEntity: Name: NameFull: Song Z – PersonEntity: Name: NameFull: Reiss KA – PersonEntity: Name: NameFull: Ford JM – PersonEntity: Name: NameFull: Chen L – PersonEntity: Name: NameFull: Rolig AS – PersonEntity: Name: NameFull: Zwiebel JA – PersonEntity: Name: NameFull: Gore SD – PersonEntity: Name: NameFull: Gray RJ – PersonEntity: Name: NameFull: Wang V – PersonEntity: Name: NameFull: McShane LM – PersonEntity: Name: NameFull: Rubinstein LV – PersonEntity: Name: NameFull: Patton D – PersonEntity: Name: NameFull: Gross J – PersonEntity: Name: NameFull: Brunnquell D – PersonEntity: Name: NameFull: Jackson LF – PersonEntity: Name: NameFull: Williams PM – PersonEntity: Name: NameFull: Hamilton SR – PersonEntity: Name: NameFull: Takebe N – PersonEntity: Name: NameFull: Brufsky A – PersonEntity: Name: NameFull: Tricoli JV – PersonEntity: Name: NameFull: Conley BA – PersonEntity: Name: NameFull: Arteaga CL – PersonEntity: Name: NameFull: Harris LN – PersonEntity: Name: NameFull: O'Dwyer PJ – PersonEntity: Name: NameFull: Chen AP – PersonEntity: Name: NameFull: Flaherty KT IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2026 Jun Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 2473-4284 Numbering: – Type: volume Value: 10 – Type: issue Value: 6 Titles: – TitleFull: JCO precision oncology Type: main |
| ResultId | 1 |
